Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone
Serge Ferrari, Bente Langdahl
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 5, pp. 307-317
Closed Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Molecular and Cellular Mechanisms of Osteoporosis
Ivan V. Zhivodernikov, Tatiana V. Kirichenko, Yuliya V. Markina, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15772-15772
Open Access | Times Cited: 40
Bone Hierarchical Structure: Heterogeneity and Uniformity
Adrián Rodríguez-Palomo, Maja Østergaard, Henrik Birkedal
Advanced Functional Materials (2023) Vol. 34, Iss. 35
Open Access | Times Cited: 19
The role of magnesium in the pathogenesis of osteoporosis
Lin Liu, Pan Luo, Pengfei Wen, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 7
Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?
Giorgia Grassi, Alberto Ghielmetti, Marta Zampogna, et al.
The Journal of Clinical Endocrinology & Metabolism (2024) Vol. 109, Iss. 10, pp. e1817-e1826
Open Access | Times Cited: 6
Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor
Yan Chen, Jiehuang Zheng, Lixia Mo, et al.
Phytomedicine (2024) Vol. 129, pp. 155688-155688
Closed Access | Times Cited: 5
Parathyroid hormone levels following denosumab vs. zoledronic acid therapy for osteoporosis
Pnina Rotman‐Pikielny, Liat Barzilai-Yosef, Erez Ramaty, et al.
Bone (2025), pp. 117407-117407
Closed Access
Research Progress on the Influence of Novel Targeted Drugs for Osteoporosis on Glucose Metabolism
Lingyang Meng, Lei Sun, Mei Li
Biomolecules (2025) Vol. 15, Iss. 3, pp. 331-331
Open Access
Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach
Olivier Lamy, Judith Everts‐Graber, Elena González Rodríguez
Aging Clinical and Experimental Research (2025) Vol. 37, Iss. 1
Open Access
The Extensive Study of Magnesium Deficiency, 25‐(OH) Vitamin D3, Inflammatory Markers, and Parathyroid Hormone in Relation to Bone Mineral Density in Iraqi Osteoporosis Patients: A Cross‐Sectional Study
Eman T. Ali, Ali N. Mohammed, Amer S. Khudairi, et al.
Health Science Reports (2025) Vol. 8, Iss. 4
Open Access
Postmenopausal Osteoporosis
William K. Silverstein, Nathan Cantor, Angela M. Cheung
New England Journal of Medicine (2024) Vol. 390, Iss. 7, pp. 673-676
Closed Access | Times Cited: 4
Progression of multiple vertebral fractures after denosumab discontinuation under treatment with romosozumab. A case-report
Michail Krikelis, Susana Gazi, George Trovas, et al.
Joint Bone Spine (2024) Vol. 91, Iss. 5, pp. 105754-105754
Closed Access | Times Cited: 4
Prussian blue nanoparticles prevent RANKL‐induced osteoclastogenesis by scavenging ROS and inactivating NF‐κB/MAPK signaling pathways
Jiancheng Yang, Qinghua Tang, S.B. Li, et al.
The FASEB Journal (2025) Vol. 39, Iss. 3
Closed Access
Sequential and Long-term Therapy for Osteoporosis
Michael R. McClung
Current Osteoporosis Reports (2025) Vol. 23, Iss. 1
Closed Access
Advances of long non-coding RNAs in osteoclast differentiation and osteoporosis
Wenjie Liu, Yunhui Zhang, Quanfeng Li, et al.
Pathology - Research and Practice (2024) Vol. 260, pp. 155413-155413
Closed Access | Times Cited: 3
A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
Yue He, Rong Zhang, Huarui Shen, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Jaw osteoporosis: Challenges to oral health and emerging perspectives of treatment
Fushuang Liu, Xuan Wang, Yikai He, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 116995-116995
Open Access | Times Cited: 2
Mapping RANKL- and OPG-expressing cells in bone tissue: the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect
Bilal Mohamad El-Masri, Christina Møller Andreasen, Kaja Søndergaard Laursen, et al.
Bone Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 2
Therapy with transitions from one bone-forming agent to another: a retrospective cohort study on Teriparatide and Romosozumab
Tomonori Kobayakawa, Yasuhide Kanayama, Y. Hirano, et al.
JBMR Plus (2024) Vol. 8, Iss. 12
Open Access | Times Cited: 2
Structure-Based Discovery of Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Induced Osteoclastogenesis Inhibitors
Vagelis Rinotas, Fotini Liepouri, Maria‐Dimitra Ouzouni, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11290-11290
Open Access | Times Cited: 4
The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis
Athanasios D. Anastasilakis, Polyzois Makras, Stergios A. Pοlyzos, et al.
Calcified Tissue International (2023) Vol. 113, Iss. 4, pp. 469-473
Closed Access | Times Cited: 4
Three-year effect of bisphosphonates on bone mineral density after Denosumab withdrawal: Observations from a real-world study
Vanina Farías, Fernando Jerkovich, Andrea Barragán, et al.
JBMR Plus (2024) Vol. 8, Iss. 6
Open Access | Times Cited: 1
Ormoni e citochine ossei target delle terapie dei disordini osteometabolici e dell’osteoporosi
Gregorio Guabello, Silvia Carrara, Sabrina Corbetta
L Endocrinologo (2024) Vol. 25, Iss. 3, pp. 286-292
Closed Access | Times Cited: 1
Lysosomal biogenesis and function in osteoclasts: a comprehensive review
Junchen Jiang, Rufeng Ren, Weiyuan Fang, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 1
Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
Athanasios D. Anastasilakis, Polyzois Makras, Julien Paccou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 18, pp. 5874-5874
Open Access | Times Cited: 3
Regorafenib Attenuates Osteoclasts Differentiation by Inhibiting the NF-κB, NFAT, ERK, and p38 Signaling Pathways
Lin Zhou, Peiru Su, Xiangya Luo, et al.
ACS Omega (2024) Vol. 9, Iss. 31, pp. 33574-33593
Open Access
Page 1 - Next Page

Scroll to top